Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy vs Observation in Stage I Ovarian Cancer
NCT04063527Phase 3Recruiting
- Sponsor
- Japanese Gynecologic Oncology Group
- Start
- Jul 2012
- Primary completion
- Oct 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, carboplatin and docetaxel in epithelial ovarian cancer (EOC) (2 arms), sponsored by Japanese Gynecologic Oncology Group. Primary endpoint: Overall Survival at 60 months. Started Jul 2012; status: recruiting.
02
Drugs
paclitaxelcarboplatindocetaxel
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04063527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063527.